CTRV - CTRV Stock Soars 40% as FDA Issues Positive Response for CRV431

CTRV stock is one of the biggest biotech stocks after ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) gets a positive response from the FDA to its pre-IND meeting for developing CRV431 in NASH.

New Jersey-based biopharmaceutical company ContraVir Pharmaceuticals, which is involved in manufacturing medicines meant for treating liver diseases originating from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, made a major announcement today. The company got a highly positive update from the United States Food and Drug Administration with regards to the company’s pre-Investigational New Drug meeting related to the product CRV 431. After having studied ...